Downregulation of HMGB1 by MiR-34a is Sufficient to Suppress Proliferation, Migration and Invasion of Human Cervical and Colorectal Cancer Cells

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2016 Jul 27

PMID 27456356

Citations 27

Authors

Karthik Subramanian Chandrasekaran

Anusha Sathyanarayanan

Devarajan Karunagaran

Affiliations

Soon will be listed here.

Abstract

High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein known to be highly expressed in human cervical (CaCx) and colorectal (CRC) cancers, and sustained high levels of HMGB1 contribute to tumourigenesis and metastasis. HMGB1-targeted cancer therapy is of recent interest, and there are not many studies on miRNA-mediated HMGB1 regulation in these cancers. Since miRNA-based therapeutics for cancer is gaining importance in recent years, it was of interest to predict miRNAs targeting HMGB1. Based on the identification of a potential miR-34a response element in HMGB1-3' untranslated region (3'UTR) and an inverse correlation between HMGB1 and miR-34a expression levels in CaCx and CRC tissues, from a subset of the local population as well as a large sampling from TCGA database, experiments were performed to validate HMGB1 as a direct target of miR-34a in CaCx and CRC cells. Ectopic expression of miR-34a decreased the wild-type HMGB1-3'UTR luciferase activity but not that of its mutant in 3'UTR luciferase assays. While forced expression of miR-34a in CaCx and CRC cells inhibited HMGB1 mRNA and protein levels, proliferation, migration and invasion, inhibition of endogenous miR-34a enhanced these tumourigenic properties. siRNA-mediated HMGB1 suppression imitated miR-34a expression in reducing proliferation and metastasis-related events. Combined with the disparity in expression of miR-34a and HMGB1 in clinical specimens, the current findings would help in not only understanding the complexity of miRNA-target regulatory mechanisms but also in designing novel therapeutic interventions in CaCx and CRC.

Citing Articles

The modulation of immune cell death in connection to microRNAs and natural products.

Chuang Y, Yen C, Tang J, Chang F, Tsai Y, Wu K Front Immunol. 2025; 15:1425602.

PMID: 39759512 PMC: 11695430. DOI: 10.3389/fimmu.2024.1425602.

The Role of High Mobility Group Box B-1 in the Prognosis of Colorectal Cancer Based on the Changes in the Intestinal Mucosal Barrier.

Zhao W, Chen A, Yuan N, Hao X, Wang C, Lu X Technol Cancer Res Treat. 2024; 23:15330338231198972.

PMID: 38200714 PMC: 10785708. DOI: 10.1177/15330338231198972.

The RNA interactome in the Hallmarks of Cancer.

Gabryelska M, Conn S Wiley Interdiscip Rev RNA. 2023; 14(5):e1786.

PMID: 37042179 PMC: 10909452. DOI: 10.1002/wrna.1786.

Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Yang Z, Liu T, Ren X, Yang M, Tu C, Li Z Cell Cycle. 2022; 21(20):2121-2131.

PMID: 35699451 PMC: 9519004. DOI: 10.1080/15384101.2022.2087755.

HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer.

Lei T, Huang J, Xie F, Gu J, Cheng Z, Wang Z Acta Biochim Biophys Sin (Shanghai). 2022; 54(4):fpage-lpage.

PMID: 35462475 PMC: 9828391. DOI: 10.3724/abbs.2022023.

References

Aherne S, Madden S, Hughes D, Pardini B, Naccarati A, Levy M . Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression. BMC Cancer. 2015; 15:329. PMC: 4417244. DOI: 10.1186/s12885-015-1327-5. View

Subramanian M, Rao S, Thacker P, Chatterjee S, Karunagaran D . MiR-29b downregulates canonical Wnt signaling by suppressing coactivators of β-catenin in human colorectal cancer cells. J Cell Biochem. 2014; 115(11):1974-84. DOI: 10.1002/jcb.24869. View

Suzuki H, Katsura A, Matsuyama H, Miyazono K . MicroRNA regulons in tumor microenvironment. Oncogene. 2014; 34(24):3085-94. PMC: 4761641. DOI: 10.1038/onc.2014.254. View

Savita U, Karunagaran D . MicroRNA-106b-25 cluster targets β-TRCP2, increases the expression of Snail and enhances cell migration and invasion in H1299 (non small cell lung cancer) cells. Biochem Biophys Res Commun. 2013; 434(4):841-7. DOI: 10.1016/j.bbrc.2013.04.025. View

Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Chai F . HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer. Tumour Biol. 2015; 36(11):9039-47. DOI: 10.1007/s13277-015-3624-7. View

Guo S, Bai R, Liu W, Zhao A, Zhao Z, Wang Y . miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol. 2014; 35(7):7025-34. DOI: 10.1007/s13277-014-1965-2. View

zur Hausen H . Papillomavirus infections--a major cause of human cancers. Biochim Biophys Acta. 1996; 1288(2):F55-78. DOI: 10.1016/0304-419x(96)00020-0. View

Haggar F, Boushey R . Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2010; 22(4):191-7. PMC: 2796096. DOI: 10.1055/s-0029-1242458. View

Hu Y, Chen H, Yu C, Xu J, Wang J, Qian J . A long non-coding RNA signature to improve prognosis prediction of colorectal cancer. Oncotarget. 2014; 5(8):2230-42. PMC: 4039159. DOI: 10.18632/oncotarget.1895. View

10.

Davalos A, Kawahara M, Malhotra G, Schaum N, Huang J, Ved U . p53-dependent release of Alarmin HMGB1 is a central mediator of senescent phenotypes. J Cell Biol. 2013; 201(4):613-29. PMC: 3653366. DOI: 10.1083/jcb.201206006. View

11.

Lewis B, Shih I, Jones-Rhoades M, Bartel D, Burge C . Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-98. DOI: 10.1016/s0092-8674(03)01018-3. View

12.

Bommer G, Gerin I, Feng Y, Kaczorowski A, Kuick R, Love R . p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007; 17(15):1298-307. DOI: 10.1016/j.cub.2007.06.068. View

13.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

14.

Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H . Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget. 2015; 6(35):37544-56. PMC: 4741947. DOI: 10.18632/oncotarget.6065. View

15.

Li X, Wang S, Chen Y, Liu G, Yang X . miR-22 targets the 3' UTR of HMGB1 and inhibits the HMGB1-associated autophagy in osteosarcoma cells during chemotherapy. Tumour Biol. 2014; 35(6):6021-8. DOI: 10.1007/s13277-014-1797-0. View

16.

Stros M, Ozaki T, Bacikova A, Kageyama H, Nakagawara A . HMGB1 and HMGB2 cell-specifically down-regulate the p53- and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J Biol Chem. 2001; 277(9):7157-64. DOI: 10.1074/jbc.M110233200. View

17.

Misso G, Di Martino M, De Rosa G, Farooqi A, Lombardi A, Campani V . Mir-34: a new weapon against cancer?. Mol Ther Nucleic Acids. 2014; 3:e194. PMC: 4222652. DOI: 10.1038/mtna.2014.47. View

18.

Andersson U, Tracey K . HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29:139-62. PMC: 4536551. DOI: 10.1146/annurev-immunol-030409-101323. View

19.

McKinney K, Prives C . Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol. 2002; 22(19):6797-808. PMC: 134028. DOI: 10.1128/MCB.22.19.6797-6808.2002. View

20.

Tang D, Kang R, Zeh 3rd H, Lotze M . High-mobility group box 1 and cancer. Biochim Biophys Acta. 2010; 1799(1-2):131-40. PMC: 2818552. DOI: 10.1016/j.bbagrm.2009.11.014. View